MY ACCOUNT | NEWSLETTER |

Focus on typhoid toxin reveals new infection mechanisms and treatment possibilities


Researchers unveiled a new mechanism by which Salmonella Typhi, the bacteria responsible for typhoid fever, promotes its ability to cause disease.

Typhoid fever claims more than 150,000 deaths per year, mostly children. Transmitted through the consumption of contaminated food or water, Salmonella Typhi uses various mechanisms, or virulence factors, to infect and thrive in its hosts. 

One of these factors is a family of molecules called AB toxins.

New research found that one lesser-known AB toxin, the PltC typhoid toxin, preferentially targets the liver and the gallbladder, and reduces bile production. 

By reducing bile acids, which have natural anti-infection properties, the PltC toxin creates conditions for S. Typhi to thrive.

“What we are most excited about is that, with a single mutation in a part of the PltC toxin that binds to the liver and the gallbladder cells, we could significantly decrease the bacteria's ability to infect mice,” says Dr. Jeongmin Song, associate professor in the department of Microbiology and Immunology at the Cornell University College of Veterinary Medicine, who led the project.

With multidrug-resistant and extensively drug-resistant strains of S. Typhi that have emerged and spread globally, Song’s discovery opens new doors to find anti-virulence strategies against typhoid. 

“Each step of the toxin’s transport and its harmful effects can be effective intervention points,” Song says.

This research was published on June 6 in the journal Science Advances. You can also find this story on Instagram and Bluesky.


Source: https://www.vet.cornell.edu/

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Dr. Marjorie Bercier Publishes Study on Novel Diagnostic Approach for Prevalent Elephant Virus

Like0
Dislike0

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

Like0
Dislike0

Feline injection site sarcomas

Like0
Dislike0

C-reactive protein concentrations in canine acute pancreatitis

Like0
Dislike0

A retrospective clinical investigation of the safety and adverse effects of pantoprazole in hospitalized ruminants

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top